Note: Ingredients listed on restricted chemical lists
EC/CAS
211-765-7/693-98-1
Name of the chemical
2-Methylimidazol (2020/217)
Concentration
<0.3
EC/CAS
201-074-9/77-99-6
Name of the chemical
1,1,1-trimethylolpropane
Concentration
≤0.3
General Information
Revision date
2025-10-02
Product name
INFRALIT EP 8074-25 - All variants
1.2.1 Relevant identified uses
Paint
Emergency telephone
+353 (0)1 809 2166, +353 (0)1 809 2566
Icons in SDS
Company Information
company name
Teknos Group Oy
e-mail address of the competent person responsible for the Safety Data Sheet
Prod-safe@teknos.com
GHS Information
Signal word
Warning
Hazard Codes
Hazard statements (CLP)
H317
Hazard statements
Code
Statements
H317
May cause an allergic skin reaction
Section 2
SECTION 2: Hazards identification
1272/2008] Classification of the substance or mixture
Product definition
Mixture
Signal word
Warning
Hazard statements
H317 - May cause an allergic skin reaction.
Prevention
P280 - Wear protective gloves. P261 - Avoid breathing dust.
Response
P302 + P352 - IF ON SKIN: Wash with plenty of water. P333 + P313 - If skin irritation or rash occurs: Get medical advice or attention. P362 + P364 - Take off contaminated clothing and wash it before reuse.
Storage
Not applicable.
Disposal
P501 - Dispose of contents and container in accordance with all local, regional, national and international regulations.
Contains
reaction product bisphenol-F-(epichlorhydrin); epoxy resin (number average molecular weight <700)
Supplemental label elements
Contains epoxy constituents. May produce an allergic reaction.
2.3 Other hazards
Product meets the criteria for PBT or vPvB according : This mixture does not contain any substances that are assessed to be a PBT or a vPvB.
Other hazards which do not result in classification
May form explosible dust-air mixture if dispersed.
2.1 Classification of the substance or mixture
Product definition : Mixture Classification according to Regulation (EC) No. 1272/2008 [CLP/GHS] Skin Sens. 1, H317 The product is classified as hazardous according to Regulation (EC) 1272/2008 as amended. See Section 16 for the full text of the H statements declared above. See Section 11 for more detailed information on health effects and symptoms.
